ConductScience.org, home

Paper35112265

State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond.

Kumar S and 3 others. Heart Fail Rev, 2022. Cited by 10 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond. Papers, record 35112265. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35112265

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
State-of-the-art review on management of end-stage heart failure in amyloidosis: transplant and beyond.
PubMed
Journal
Heart Fail Rev
PubMed
Year
2022
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
10
iCite
Relative citation ratio, by iCite
0.76
iCite
Revised in PubMed
2026-10-28
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kumar SSalil
2Li DDaniel
3Joseph DDenny
4Trachtenberg BBarry

Source PubMed

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AmyloidosisMajor topic
Heart FailureMajor topic
Heart TransplantationMajor topic
Humans

Source PubMed

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129,954,863Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition.Proc Natl Acad Sci U S A2018https://conductscience.org/library/papers/29954863PubMed
214,734,330High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.Ann Intern Med2004https://conductscience.org/library/papers/14734330PubMed
320,733,534Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.Transplantation2010https://conductscience.org/library/papers/20733534PubMed
41,540,601Heart transplantation for restrictive cardiomyopathy: development of cardiac amyloidosis in preexisting monoclonal gammopathy.J Heart Lung Transplant1992https://conductscience.org/library/papers/1540601PubMed
51,934,428Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey.Circulation1991https://conductscience.org/library/papers/1934428PubMed
629,677,073Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis.Transplantation2018https://conductscience.org/library/papers/29677073PubMed
721,828,140Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.Blood2011https://conductscience.org/library/papers/21828140PubMed
833,621,542Cardiac transplantation outcomes in patients with amyloid cardiomyopathy.Am Heart J2021https://conductscience.org/library/papers/33621542PubMed
930,759,167Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma.PLoS One2019https://conductscience.org/library/papers/30759167PubMed
109,052,371Effectiveness of cardiac transplantation for primary (AL) cardiac amyloidosis.Am J Cardiol1997https://conductscience.org/library/papers/9052371PubMed
1131,978,210Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.Blood2020https://conductscience.org/library/papers/31978210PubMed
1228,615,223Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.Blood2017https://conductscience.org/library/papers/28615223PubMed
137,572,642Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival.Am J Cardiol1995https://conductscience.org/library/papers/7572642PubMed
1411,156,673Long term results of heart transplantation in patients with amyloid heart disease.Heart2001https://conductscience.org/library/papers/11156673PubMed
1532,917,391Outcomes of Heart Transplantation in Cardiac Amyloidosis Patients: A Single Center Experience.Transplant Proc2021https://conductscience.org/library/papers/32917391PubMed
164,872,136A clinical analysis of the course and prognosis of forty-two patients with amyloidosis.Am J Med1968https://conductscience.org/library/papers/4872136PubMed
1729,802,083Interagency registry for mechanically assisted circulatory support report on the total artificial heart.J Heart Lung Transplant2018https://conductscience.org/library/papers/29802083PubMed
1832,241,538Percutaneous Left Axillary Artery Placement of Intra-Aortic Balloon Pump in Advanced Heart Failure Patients.JACC Heart Fail2020https://conductscience.org/library/papers/32241538PubMed
1916,210,334Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis.Blood2006https://conductscience.org/library/papers/16210334PubMed
2032,623,785United network for organ sharing outcomes after heart transplantation for al compared to ATTR cardiac amyloidosis.Clin Transplant2020https://conductscience.org/library/papers/32623785PubMed

See all 51 references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 10 citations.

PMIDTitleJournalYearIn PapersSource
41,524,065A Comprehensive Review of the Management of Light-Chain (AL) and Transthyretin (ATTR) Cardiac Amyloidosis.Rev Cardiovasc Med2025https://conductscience.org/library/papers/41524065PubMed
40,335,224Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy.JACC Heart Fail2025https://conductscience.org/library/papers/40335224PubMed
39,551,565Evolving Strategies in Cardiac Amyloidosis: From Mechanistic Discoveries to Diagnostic and Therapeutic Advances.Cardiol Clin2025https://conductscience.org/library/papers/39551565PubMed
37,190,153Cardiotoxicity, Cardioprotection, and Prognosis in Survivors of Anticancer Treatment Undergoing Cardiac Surgery: Unmet Needs.Cancers (Basel)2023https://conductscience.org/library/papers/37190153PubMed
36,620,138Left ventricular myocardial work index and short-term prognosis in patients with light-chain cardiac amyloidosis: a retrospective cohort study.Quant Imaging Med Surg2023https://conductscience.org/library/papers/36620138PubMed

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TTR7,276PubTator's text mininghttps://conductscience.org/library/genes/7276

Source NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35112265

GET https://conductscience.org/api/papers/v1/35112265/references?page=2